BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World J Gastroenterol 2012; 18(30): 4004-4011 [PMID: 22912551 DOI: 10.3748/wjg.v18.i30.4004]
URL: https://www.wjgnet.com/1007-9327/full/v18/i30/4004.htm
Number Citing Articles
1
James R. Bailey, Ashish Aggarwal, Thomas F. Imperiale. Colorectal Cancer Screening: Stool DNA and Other Noninvasive ModalitiesGut and Liver 2016; 10(2): 204 doi: 10.5009/gnl15420
2
Nasimeh Vatandoost, Jahanafrooz Ghanbari, Mahboobeh Mojaver, Amir Avan, Majid Ghayour-Mobarhan, Reza Nedaeinia, Rasoul Salehi. Early detection of colorectal cancer: from conventional methods to novel biomarkersJournal of Cancer Research and Clinical Oncology 2016; 142(2): 341 doi: 10.1007/s00432-015-1928-z
3
Zongwei Li, Peng Yang, Zhuoyu Li. The multifaceted regulation and functions of PKM2 in tumor progressionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer 2014; 1846(2): 285 doi: 10.1016/j.bbcan.2014.07.008
4
Fabrizio Maria Gili, Luca Cabianca, Gian Paolo Caviglia. Utilizzo del test per la quantificazione dell’M2-PK fecale nell’ambito di un programma di screening per il carcinoma colorettale in soggetti positivi al FITLa Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 2016; 12(2): 119 doi: 10.1007/s13631-016-0120-z
5
Divya B. Bhatt, Valerie-Sue Emuakhagbon. Current Trends in Colorectal Cancer ScreeningCurrent Colorectal Cancer Reports 2019; 15(2): 45 doi: 10.1007/s11888-019-00432-4
6
Paul Dowling, David J. Hughes, Anne Marie Larkin, Justine Meiller, Michael Henry, Paula Meleady, Vincent Lynch, Barbara Pardini, Alessio Naccarati, Miroslav Levy, Pavel Vodicka, Paul Neary, Martin Clynes. Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancerClinica Chimica Acta 2015; 441: 133 doi: 10.1016/j.cca.2014.12.005
7
Mirko Di Ruscio, Filippo Vernia, Antonio Ciccone, Giuseppe Frieri, Giovanni Latella. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?Inflammatory Bowel Diseases 2018; 24(1): 78 doi: 10.1093/ibd/izx011
8
Marc Tänzer, Magdalena Liebl, Michael Quante. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinomaPharmacology & Therapeutics 2013; 140(2): 133 doi: 10.1016/j.pharmthera.2013.06.005
9
C. P. Pox. Screening des kolorektalen Karzinomscoloproctology 2016; 38(2): 141 doi: 10.1007/s00053-015-0080-1
10
Ze Qian, Wendi Hu, Zhen Lv, Hua Liu, Diyu Chen, Yacong Wang, Jian Wu, Shusen Zheng. PKM2 upregulation promotes malignancy and indicates poor prognosis for intrahepatic cholangiocarcinomaClinics and Research in Hepatology and Gastroenterology 2020; 44(2): 162 doi: 10.1016/j.clinre.2019.06.008
11
Paolo Battaglia, Elisabetta Baritono, Andrea Remo, Roberto Vendraminelli, Antonio Conti. KRAS Mutations and M2PK Upregulation in Stool Samples from Individuals with Positive Fecal Occult Blood Tests Screened for Colorectal CancerTumori Journal 2014; 100(2): 122 doi: 10.1177/030089161410000202
12
Christian P. Pox. Controversies in Colorectal Cancer ScreeningDigestion 2014; 89(4): 274 doi: 10.1159/000363287
13
Yoshikatsu Koga, Nobuyoshi Yamazaki, Yasuhiro Matsumura. New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNAExpert Review of Molecular Diagnostics 2014; 14(1): 107 doi: 10.1586/14737159.2014.863152
14
KhalidAhmad Al-Sindi, MulazimHussain Bukhari, MohmedAli Al-Hamar. Role of a noninvasive stool-based molecular test in screening and early detection of colorectal cancersActa Medica International 2019; 6(2): 82 doi: 10.4103/ami.ami_27_19
15
Rashid N. Lui, Sunny H. Wong, Nik Sheng Ding, Masau Sekiguchi, Jun Yu, Tiing‐Leong Ang, Khay‐Guan Yeoh, Han‐Mo Chiu, Joseph J. Y. Sung. Is this the end of colonoscopy screening for colorectal cancer? An Asia‐Pacific perspectiveJournal of Gastroenterology and Hepatology 2023; 38(5): 671 doi: 10.1111/jgh.16182
16
Elisabeth Waldmann, Jaroslaw Regula, Monika Ferlitsch. How Can Screening Colonoscopy Be Optimized?Digestive Diseases 2015; 33(1): 19 doi: 10.1159/000366033
17
Vibhor Gupta, Mohd Askandar Iqbal, Bhupender Kumar, Rameshwar N. K. Bamezai. Tumor Cell Metabolism2015; : 123 doi: 10.1007/978-3-7091-1824-5_6
18
Kang-Moon Lee. Fecal Biomarkers in Inflammatory Bowel DiseaseIntestinal Research 2013; 11(2): 73 doi: 10.5217/ir.2013.11.2.73
19
Romain Villéger, Amélie Lopès, Julie Veziant, Johan Gagnière, Nicolas Barnich, Elisabeth Billard, Delphine Boucher, Mathilde Bonnet. Microbial markers in colorectal cancer detection and/or prognosisWorld Journal of Gastroenterology 2018; 24(22): 2327-2347 doi: 10.3748/wjg.v24.i22.2327
20
Yong Cheol Kim, Jeong Ho Kim, Dae Young Cheung, Tae Ho Kim, Eun Jung Jun, Jung-Whan Oh, Chang Whan Kim, Woo Chul Chung, Byung-Wook Kim, Sung Soo Kim, Jin Il Kim, Soo-Heon Park, Jae Kwang Kim. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase TestGut and Liver 2015; 9(5) doi: 10.5009/gnl13457
21
Maru Kim, Hyung-Jin Kim, In Kyu Lee, Seong-Taek Oh, Kyungja Han. Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screeningEuropean Surgery 2017; 49(3): 127 doi: 10.1007/s10353-017-0464-2
22
Tamara Pang, Steven T Leach, Tamarah Katz, Adam Jaffe, Andrew S Day, Chee Y Ooi. Elevated fecal M2‐pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood?Journal of Gastroenterology and Hepatology 2015; 30(5): 866 doi: 10.1111/jgh.12842
23
N. S. Sergeeva, Nina V. Marshutina, Ye. V. Zenkina. Stool immunoassay for identification of colorectal cancer and other significant gastrointestinal diseases risk groupsRussian Journal of Gastroenterology, Hepatology, Coloproctology 2016; 26(2): 50 doi: 10.22416/1382-4376-2016-26-2-50-57
24
Edward Sanders, Svenja Diehl. Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinomaOncoscience 2015; 2(2): 151 doi: 10.18632/oncoscience.128
25
Shahidah Che Alhadi, Wan Zainira Wan Zain, Zalina Zahari, Mohd Nizam Md Hashim, Syed Hassan Syed Abd. Aziz, Zaidi Zakaria, Michael Pak-Kai Wong, Andee Dzulkarnaen Zakaria. The Use of M2-Pyruvate Kinase as a Stool Biomarker for Detection of Colorectal Cancer in Tertiary Teaching Hospital: A Comparative StudyAnnals of Coloproctology 2020; 36(6): 409 doi: 10.3393/ac.2020.08.27
26
Petra Hudler, Nina Kocevar, Radovan Komel. Proteomic Approaches in Biomarker Discovery: New Perspectives in Cancer DiagnosticsThe Scientific World Journal 2014; 2014: 1 doi: 10.1155/2014/260348
27
Mohd Askandar Iqbal, Vibhor Gupta, Prakasam Gopinath, Sybille Mazurek, Rameshwar N.K. Bamezai. Pyruvate kinase M2 and cancer: an updated assessmentFEBS Letters 2014; 588(16): 2685 doi: 10.1016/j.febslet.2014.04.011
28
Suresh Sithambaram, Ida Hilmi, Khean-Lee Goh, Lanjing Zhang. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test- A Rapid Office Based Assay Test for the Detection of Colorectal CancerPLOS ONE 2015; 10(7): e0131616 doi: 10.1371/journal.pone.0131616
29
Chia-Long Lee, Chi-Jung Huang, Shung-Haur Yang, Chun-Chao Chang, Chi-Cheng Huang, Chih-Cheng Chien, Ruey-Neng Yang. Discovery of genes from feces correlated with colorectal cancer progressionOncology Letters 2016; 12(5): 3378 doi: 10.3892/ol.2016.5069
30
C. P. Pox, F. Kühn, E. Klar. DarmkrebsfrüherkennungDer Onkologe 2016; 22(8): 529 doi: 10.1007/s00761-016-0048-y
31
Hisham K. Dabbous, Yosry Abd El-Rahman Mohamed, Runia F. El-Folly, Mohamed D. El-Talkawy, Hani E. Seddik, Dina Johar, Mohammed A. Sarhan. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal CancerJournal of Gastrointestinal Cancer 2019; 50(3): 442 doi: 10.1007/s12029-018-0088-1
32
Abdo Alnabulsi, Graeme I. Murray. Proteomics for early detection of colorectal cancer: recent updatesExpert Review of Proteomics 2018; 15(1): 55 doi: 10.1080/14789450.2018.1396893
33
Sally C. Benton, Helen E. Seaman, Stephen P. Halloran. Faecal Occult Blood Testing for Colorectal Cancer Screening: the Past or the FutureCurrent Gastroenterology Reports 2015; 17(2) doi: 10.1007/s11894-015-0428-2
34
Jeremy R Huddy, Melody Z Ni, Sheraz R Markar, George B Hanna. Point-of-care testing in the diagnosis of gastrointestinal cancers: Current technology and future directionsWorld Journal of Gastroenterology 2015; 21(14): 4111-4120 doi: 10.3748/wjg.v21.i14.4111
35
Chiara Rosso, Luca Cabianca, Fabrizio M. Gili. Non-invasive markers to detect colorectal cancer in asymptomatic populationMinerva Biotecnologica 2019; 31(1) doi: 10.23736/S1120-4826.18.02493-X
36
Sarah Cheuk Hei Chan, Jessie Qiaoyi Liang. Advances in tests for colorectal cancer screening and diagnosisExpert Review of Molecular Diagnostics 2022; 22(4): 449 doi: 10.1080/14737159.2022.2065197
37
Abeer Hammoudi, Fei Song, Karen R. Reed, Rosalind E. Jenkins, Valerie S. Meniel, Alastair J.M. Watson, D. Mark Pritchard, Alan R. Clarke, John R. Jenkins. Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of human colorectal cancer (CRC)Biochemical and Biophysical Research Communications 2013; 440(3): 364 doi: 10.1016/j.bbrc.2013.08.076
38
Mariann Rutka, Renáta Bor, Anita Bálint, Anna Fábián, Ágnes Milassin, Ferenc Nagy, Zoltán Szepes, Mónika Szűcs, László Tiszlavicz, Klaudia Farkas, Tamás Molnár. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the ColorectumMediators of Inflammation 2016; 2016: 1 doi: 10.1155/2016/2492081
39
Philip D. Hardt. Tumor Cell Metabolism2015; : 165 doi: 10.1007/978-3-7091-1824-5_8
40
Jacqueline I. Keenan, Frank A. Frizelle. Biomarkers to Detect Early-Stage Colorectal CancerBiomedicines 2022; 10(2): 255 doi: 10.3390/biomedicines10020255